Ribeirão Preto Medical School -University of São Paulo, Ribeirão Preto, Brazil, 5 University of São paulo, Ribeirão Preto Medical School, Ribeirão Preto, Brazil. RATIONALE: Aspirin exacerbated respiratory disease (AERD) is characterized by chronic rhinosinusitis with nasal polyps, asthma and hypersensitivity to Aspirin/NSAIDs. Increased levels of periostin have been described in patients with AERD. We evaluated serum periostin in Brazilian patients with AERD, and compared to patients with Perennial Allergic Rhinitis (PAR) and healthy individuals. METHODS: Twenty-nine patients (20F/9M) with AERD underwent polyp biopsy through nasofibroscopy. Control groups of 12 patients with PAR (9F/3M) and 19 healthy subjects (11F/8M) had samples collected during rhinoplasty. Eosinophils were quantitated in blood, and in polyp tissue or nasal mucosa. Total IgE was determined by ImmunoCAP, and serum periostin by ELISA. Eosinophils in high power field (HPF), eosinophils/mm3 in blood, total IgE and serum periostin levels in patients with AERD were compared with those with PAR and healthy subjects. RESULTS: Patients with AERD were older than patients with PAR patients and healthy controls (median 54, 30 and 29 years, respectively, p50.0001). Peripheral blood eosinophils were higher in AERD as compared to PAR and healthy individuals (median 640/mm3, 200/mm3 and 100/mm3). Median tissue eosinophils were 113.3, 2.5 and 0.7cells/ HPF in AERD, RAP and healthy individuals, respectively (p< 0.05). Mean serum periostin levels were 109.9ng/ml(range 59.4-236.6); 102.4ng/ mL(range 57.9-147.8); and 83.6ng/mL(range 40.1-139.5), in AERD, RAP and healthy individuals, respectively (AERD vs. healthy subjects, p50.01). CONCLUSIONS: In a subset of Brazilian patients with AERD, we observed higher blood and tissue eosinophils, as compared to patients with PAR and healthy individuals, and elevated serum periostin, indicating a strong type 2 response in AERD patients in our area.
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The effect of gastroesophageal reflux and proton pump inhibitors on respiratory tract infections in patients with asthma RATIONALE: Co-morbid gastroesophageal reflux disease (GERD) is a significant factor associated with poor asthma control. Treatment with proton pump inhibitors (PPIs) have not consistently improved asthma control and there is evidence that PPIs may increase the risk of respiratory tract infections (RTIs). We aimed to study how GERD diagnosis and PPI treatment affect the risk of RTIs and related sequelae among children and adults with asthma. METHODS: RTIs and RTI-related morbidity from four large asthma trials were analyzed for associations with self-reported GERD and PPI use. The primary outcome was rate of visits with an RTI, documented using standardized clinic visit interviews. Secondary outcomes included asthma exacerbations requiring systemic steroids. Multivariable negative binomial regression was used. Models controlled for age, gender, ethnicity, race, BMI classification, atopy, use of H2 antagonists or antacids, GERD symptom frequency, and study. RESULTS: There were 1181 total subjects: 643 children (58 with GERD, 162 on a PPI) and 538 adults (138 with GERD, 78 with a PPI). In children, GERD did not increase the rate of RTI or RTI-related asthma exacerbations. PPI use was associated with increased rates of RTIs (rate ratio 1.2, 95% CI 1.0-1.4, p50.04) and RTI-related asthma exacerbations (rate ratio51.8, 95% CI 1.1-3.0, p50.02). In adults, GERD and PPI use did not affect the rates of RTIs or RTI-related asthma exacerbations. CONCLUSIONS: Independent of GERD, PPI use is associated with increased rates of RTI and associated asthma exacerbations in children but not adults with asthma.
